In this study we investigated choline MRS and parameters obtained from the histogram analysis of the ADC distribution as early markers of response to MAPK targeting via combined BRAF and MEK inhibition, in BRAFV600E vemurafenib-sensitive and resistant melanoma xenografts. The gene discussed is BRAF; the disease is melanoma.